mProX™ Human ADORA2B Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human ADORA2B Stable Cell Line (S01YF-0923-PY4). Click the button above to contact us or submit your feedback about this product.
David (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Shirley (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 ADORA2B is a Fra-1 target gene contributing to metastatic activity of breast cancer cells.
The luminescence signal in the lungs of mice, injected intravenously with 2×10^5 LM2 cells expressing either a control or sh-ADORA2B vector, was quantified at various time intervals. A sample size of 6 was used for analysis, with error bars denoting standard error. Statistical significance (*P < 0.05, **P < 0.01) was determined via a two-tailed Wilcoxon signed-rank test, comparing both sh-ADORA2B groups to the control.
Ref: Desmet, Christophe J., et al. "Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis." Proceedings of the National Academy of Sciences 110.13 (2013): 5139-5144.
Pubmed: 23483055
DOI: 10.1073/pnas.1222085110
Research Highlights
Kim S, et al. "Canine Somatic Mutations from Whole-Exome Sequencing of B-Cell Lymphomas in Six ." Animals : an open access journal from MDPI, 2023.
Canine lymphoma (CL) is a prevalent malignant tumor that affects dogs. Its exact causes are still unknown. Some researchers propose that genetic mutations may contribute to the development of CL, but the mechanisms behind this are not fully understood. One approach to identifying these mutations is through whole-exome sequencing (WES), a cost and time-efficient method that focuses solely on the protein-coding regions of the genome. In this study, eight patients with B-cell lymphomas were examined using WES on both blood and lymph node aspirate samples, resulting in the identification of 17 somatic variants (GOLIM4, ITM2B, STN1, UNC79, PLEKHG4, BRF1, ENSCAFG00845007156, SEMA6B, DSC1, TNFAIP1, MYLK3, WAPL, ADORA2B, LOXHD1, GP6, AZIN1, and NCSTN) with potential impact on the disease. Further analysis also revealed 16 relevant pathways through Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. These findings suggest that these identified mutations may play a significant role in CL, requiring further research to confirm their involvement.
Pubmed:
37760246
DOI:
10.3390/ani13182846
Simard T, et al. "Dipyridamole and vascular healing following stent implantation.." Frontiers in cardiovascular medicine, 2023.
The study aimed to determine whether Dipyridamole (DP), an approved therapeutic agent, could mitigate in-stent restenosis (ISR) in patients undergoing coronary stent implantation. 24 New Zealand White rabbits were randomized to receive DP or a control treatment for 6 weeks after stent implantation, followed by assessment of neointimal tissue (NI) volume and stent strut healing using optical coherence tomography (OCT) and histology. Results showed a significant reduction in NI burden and an increase in properly healed stent struts with DP treatment, as well as a decrease in smooth muscle cell (SMC) content. In vitro experiments supported the role of DP in inhibiting SMC proliferation through the adenosine receptor-A2B (ADOR-A2B). However, the effects were attenuated in rabbits with atherosclerosis. It is suggested that clinical trials be conducted to evaluate the efficacy of DP as an additional therapy for preventing adverse events in patients with coronary stents.
Pubmed:
37745122
DOI:
10.3389/fcvm.2023.1130304
